Pharmaceuticals

Global Liver Cancer Therapeutics Market Valuation and Growth Prospects: $5.45 Billion by 2029

December 4, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the liver cancer therapeutics market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Liver Cancer Therapeutics Market Size?

The liver cancer therapeutics market has witnessed rapid growth in its size during recent years. It is anticipated to expand from $2.52 billion in 2024 to $2.94 billion in 2025, progressing at a compound annual growth rate (CAGR) of 16.8%. The increase observed in the historic period is attributable to increasing funding from government and non-profits, rising healthcare expenditure globally, expanding health insurance coverage in developing countries, aging global population, and increasing prevalence of obesity and diabetes.

The liver cancer therapeutics market size is anticipated to undergo significant expansion over the coming years. This market is projected to reach $5.45 billion by 2029, driven by a compound annual growth rate (CAGR) of 16.7%. The expected growth during the forecast period can be attributed to the increasing global incidence of liver cancer, the high prevalence of hepatitis B and C infections, a rise in alcohol-related liver disease, growing instances of non-alcoholic fatty liver disease, and the expanding adoption of immunotherapy approaches. Prominent trends throughout the forecast period include the integration of AI and ML in drug discovery, the utilization of big data and real-world evidence in clinical trials, the development of advanced imaging technologies, the adoption of minimally invasive diagnostic tools, and the increasing role of telemedicine and digital health in oncology follow-up care.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24283&type=smp

What Core Market Drivers Are Expanding The Liver Cancer Therapeutics Industry?

An increase in hepatitis B infection rates is expected to drive expansion in the liver cancer therapeutics market in the future. Hepatitis B infection is defined as a viral illness, stemming from the hepatitis B virus (HBV), which predominantly impacts the liver and can result in both immediate (acute) and prolonged (chronic) health issues, such as liver cancer. This increase in hepatitis B infections is partially attributed to a rise in injection drug use, facilitating viral transmission via shared contaminated needles and syringes. Treatment solutions for liver cancer are necessary for hepatitis B infections because chronic exposure can cause ongoing liver inflammation and cellular harm, substantially elevating the likelihood of developing cancerous liver conditions over time. As an illustration, a report released in April 2024 by the World Health Organization (WHO), an intergovernmental body based in Switzerland, indicated that in 2022, more than 254 million individuals globally were positive for hepatitis B, with an additional 1.2 million new cases documented. Moreover, hepatitis B contributed to 83% of the 1.3 million viral hepatitis-related fatalities reported globally. Consequently, the growing occurrence of hepatitis B infections is projected to stimulate the expansion of the liver cancer therapeutics market.

What Segment Insights Are Highlighted In The Liver Cancer Therapeutics Market Report?

The liver cancer therapeutics market covered in this report is segmented –

1) By Type: Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Other Types

2) By Therapy Type: Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, Other Therapy Types

3) By Distribution Channel Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End-Users: Pediatrics, Adults

Subsegments:

1) By Hepatocellular Carcinoma: Localized Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma

2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma

3) By Hepatoblastoma: Standard-Risk Hepatoblastoma, High-Risk Hepatoblastoma, Metastatic Hepatoblastoma

4) By Other Types: Fibrolamellar Carcinoma, Angiosarcoma Of The Liver, Hemangiosarcoma

Which Notable Trends Are Transforming The Liver Cancer Therapeutics Market Outlook?

Leading companies within the liver cancer therapeutics market are concentrating on developing innovative treatments, such as prescription immunotherapy medications, with the aim of providing long-lasting effects. These prescription immunotherapy drugs function by either enhancing or suppressing the body’s immune system to help combat specific diseases, including cancer or chronic infections, by precisely targeting and modulating immune responses. For instance, in April 2025, Bristol Myers Squibb, a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for Opdivo (nivolumab) and Yervoy (ipilimumab) for adult patients with hepatocellular carcinoma (HCC), the most prevalent primary liver cancer, that is either incurable or has spread, as a first-line treatment. A distinctive aspect of this product is that its authorization stems from the outcomes of the global Phase 3 randomized, open-label CheckMate-9DW trial. In this investigation, patients suffering from metastatic or incurable HCC who had not previously received systemic therapy were randomly assigned to a regimen that included Opdivo plus Yervoy, alongside the investigator’s chosen tyrosine kinase inhibitor monotherapy (lenvatinib or sorafenib). This combination therapy showcased statistically notable enhancements in overall survival (OS) and overall response rate (ORR) when benchmarked against the comparator arm, distinguishing it as the sole trial underpinning an FDA approval that has presented superior outcomes in this context.

Which Firms Are Driving Innovation Within The Liver Cancer Therapeutics Market?

Major companies operating in the liver cancer therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca PLC, Amgen Inc., Eli Lilly and Company , Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Ipsen, Exelixis Inc., BeiGene Ltd., Hutchmed, Celgene Corporation, Zymeworks Inc., Can-Fite BioPharma, Onyx Pharmaceuticals Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/liver-cancer-therapeutics-global-market-report

What Regional Trends Are Shaping Growth In The Liver Cancer Therapeutics Market?

North America was the largest region in the liver cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24283&type=smp

Browse Through More Reports Similar to the Global Liver Cancer Therapeutics Market 2025, By The Business Research Company

Blood Pressure Monitoring Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-pressure-monitoring-devices-global-market-report

Liver Diseases Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Liver Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795